New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
08:03 EDTHALOHalozyme announces that rrial of Hylenex recombinant met primary endpoint
Halozyme announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex recombinant and a new formulation of Hylenex currently under FDA review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion in comparison to no pre-treatment. In accordance with the trial protocol pre-specified analysis of the endpoints, data from the two patient groups treated with Hylenex formulations were pooled in comparison to a group consisting of patients using standard CSII with rapid acting analog insulin alone. Adverse events were similar across the treatment and control groups. The most common treatment related adverse event in the Hylenex groups was mild infusion site discomfort.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
10:17 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
January 12, 2015
09:15 EDTHALOHalozyme sees FY15 revenue $85M-$95M, consensus $97.23M
Subscribe for More Information
09:15 EDTHALOHalozyme anticipates expanding and accelerating PEGPH20 development efforts
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use